Allarity Therapeutics, Inc. (ALLR) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing personalized cancer treatments using its Drug Response Predictor (DRP) platform. The lead drug candidate is Stenoparib. This report covers the quarterly period ended June 30, 2024. On April 9, 2024, the Company effected a 1-for-20 reverse stock split; all share data is adjusted to reflect this.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(5,472) | $(5,732) |
| Net Loss Attributable to Common Stockholders | $(5,549) | $(13,142) |
| Cash and Cash Equivalents (End of Period) | $19,233 | $420 |
| Net Cash Used in Operating Activities | $(8,703) | $(5,697) |
| Net Cash Provided by Financing Activities | $27,689 | $4,023 |
| Total Current Liabilities | $10,616 | $14,167 |
| Convertible Promissory Notes (Current) | $1,325 | $1,300 |
Note: The Company has no revenue. Net loss is driven by operating expenses offset by non-cash gains from changes in fair value of derivative liabilities.
Material Changes vs. Prior Period
- Liquidity Improvement: Cash and cash equivalents increased significantly from $166,000 at year-end 2023 to $19.2 million at June 30, 2024, primarily due to $27.7 million in net proceeds from an At-The-Market (ATM) equity offering.
- Operating Expenses: Total operating expenses decreased slightly to $7.6 million for the six months ended June 30, 2024, compared to $7.8 million in the prior year period. Research and Development (R&D) expenses increased by $696,000 due to higher manufacturing and study costs, while General and Administrative (G&A) expenses decreased by $909,000 due to cost-cutting measures.
- Debt and Derivatives: The Company redeemed 3i Convertible Senior Promissory Notes in full in May 2024. Warrant derivative liabilities decreased from $3.1 million at year-end 2023 to $16,000 at June 30, 2024, resulting in a significant non-cash gain of $2.7 million in the income statement.
- Preferred Stock: All outstanding Series A Convertible Preferred Stock was converted to common stock during the period.
Guidance, Outlook, Risks, and Contingencies
- Liquidity Outlook: Management believes existing cash of $19.2 million is sufficient to fund operations for at least the next 12 months. However, the Company expects to continue incurring losses and will require additional capital for future clinical trials and commercialization.
- SEC Investigation: On July 19, 2024, the Company received a "Wells Notice" from the SEC regarding disclosures related to FDA meetings for its Dovitinib NDA submitted in 2021. The SEC staff preliminarily recommends an enforcement action alleging violations of federal securities laws. The Company intends to respond formally.
- Nasdaq Delisting Risk: The Company received notice of non-compliance with Nasdaq's $1.00 minimum bid price rule. A hearing was held on July 30, 2024, and a ruling is expected within two weeks of that date.
- Novartis Termination: A license agreement with Novartis was terminated in January 2024 due to a material breach. Liabilities totaling approximately $5.1 million (including accounts payable and convertible notes) became immediately due and payable.
- Eisai License: The Company is renegotiating terms with Eisai regarding Stenoparib, including a postponed payment of $850,000 originally due March 1, 2024.
Investor Verification Checklist
- SEC Wells Notice Status: Verify the outcome of the SEC enforcement recommendation and potential financial or reputational impact.
- Nasdaq Compliance: Confirm the ruling on the bid price deficiency and the Company's plan to regain compliance to avoid delisting.
- Novartis Liability: Assess the Company's ability to service the immediate debt obligations (~$5.1M) resulting from the Novartis termination.
- Capital Sufficiency: Monitor cash burn rates against the $19.2M cash balance to validate the 12-month runway estimate.
- ATM Offering Progress: Track the remaining capacity under the $30M ATM agreement and the pace of share sales.